

Mark G Ward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3755353/publications.pdf>

Version: 2024-02-01

35
papers

684
citations

758635

12
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

955
citing authors

#	ARTICLE	IF	CITATIONS
1	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1037-1053.	1.9	225
2	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 150-161.	1.9	53
3	Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 542-556.	0.6	50
4	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 612-628.	1.9	49
5	Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2839-2847.	0.9	42
6	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1135-1145.	1.9	40
7	Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877278.	1.4	38
8	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1551-1562.	1.9	38
9	Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. <i>United European Gastroenterology Journal</i> , 2017, 5, 563-570.	1.6	30
10	Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1555-1565.	0.9	21
11	Is there a role for thioguanine therapy in IBD in 2017 and beyond?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 473-486.	1.4	16
12	Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. <i>Internal Medicine Journal</i> , 2020, 50, 798-804.	0.5	12
13	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1342-1352.	1.9	11
14	Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1580-1589.	1.4	9
15	A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1909-1918.	0.9	9
16	The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. <i>Internal Medicine Journal</i> , 2010, 40, 819-827.	0.5	7
17	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228.	0.3	7
18	Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 990-998.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Therapeutic drug monitoring in inflammatory bowel disease: too little too early? comments on the American Gastroenterology Association Guideline. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 113-113.	1.5	4
20	De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months. <i>Digestive Diseases and Sciences</i> , 2022, 67, 259-262.	1.1	4
21	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2015, 21, 11331.	1.4	3
22	Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 10-11.	1.4	3
23	Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1527-1536.	0.6	2
24	PTU-078 prospective evaluation of adalimumab drug levels and anti-drug antibodies using two commercial elisa and the influence of 6-thioguanine nucleotides amongst patients with inflammatory bowel disease:. <i>Gut</i> , 2015, 64, A95.1-A95.	6.1	1
25	Research topic: Managing compassionate therapy the role of the virtual clinic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 44-45.	1.4	1
26	Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy early promise but more data needed. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 816-817.	1.9	1
27	Editorial: balancing safety and efficacy TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 554-555.	1.9	1
28	Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure out of sight but not out of mind. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1317-1318.	1.9	1
29	Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 692-695.	1.0	1
30	Editorial: escalation to weekly dosing in adalimumab-treated patients with active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 730-731.	1.9	0
31	PTU-076 faecal calprotectin (FC) a reliable marker of isolated small bowel crohn's disease (CD) activity?:. <i>Gut</i> , 2015, 64, A93.3-A94.	6.1	0
32	PTU-077 Association between crohn's disease activity and therapeutic drug monitoring of thiopurines and infliximab comparing free and total antidrug antibody measurement: Abstract PTU-077 Table 1. <i>Gut</i> , 2015, 64, A94-A94.	6.1	0
33	PWE-013...Should The Target TGN Range Be Different in Those with Intermediate Compared with Normal TPMT Activity?. <i>Gut</i> , 2016, 65, A143.2-A143.	6.1	0
34	Editorial: variability in adalimumab trough and peak serum concentrations authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1476-1477.	1.9	0
35	Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 465-465.	1.9	0